Efficacy and Safety of Low Dose Vandetanib in Metastatic Medullary Thyroid Cancer

#1758

Introduction: Medullary thyroid cancer (MTC) is an aggressive thyroid malignancy. Vandetanib is a tyrosine kinase inhibitor approved for locally advanced or metastatic MTC, administered orally 300 mg/daily. Diarrhea, hypertension and QT prolongation are common side effects and may require withdrawal or dose reduction.

Aim(s): Aim of this study was to evaluate efficacy and safety of low dose vandetanib (200 mg/daily) in progressive metastatic MTC.

Materials and methods: Clinical, biochemical and radiological records of 6 patients with metastatic MTC were retrospectively evaluated. All pts were negative for RET mutation and had progressive disease after surgery and experimental therapy with pasireotide.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Modica R

Authors: Modica R, Pizza G, Lo Calzo F, De Cicco F, Sciammarella C,

Keywords: medullary thyroid cancer, tyrosine kinase inhibitor,